Activity Overview
This educational activity is an archive of the live presentation held from February 26, 2026, through February 28, 2026.
For more
information about this educational activity, faculty, and disclosures, please
click here.
Target Audience
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Evaluate recent clinical trial results on approved and emerging therapeutic approaches for patients with hematologic disorders
- Interpret the latest guidelines and evidence for the use of biomarker-driven strategies to stratify risk and select appropriate therapies for patients with hematologic disorders
- Describe best practices for mitigating and managing treatment-related adverse events in patients with hematologic disorders
Ajai Chari, MD
Professor, Medicine
Director, Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, CA
Naval G. Daver, MD (Co-Chair)
Professor of Medicine
Co-Lead, Section of AML
Director, Leukemia Research Alliance Program
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
André H. Goy, MD (Co-Chair)
Vice President Physician in Chief Oncology
Chairman & Chief Physician Officer – John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine
Professor of Medicine – Georgetown University
Hackensack, NJ
María-Victoria Mateos, MD, PhD
Associate Professor of Medicine
Director, Myeloma Program
University of Salamanca
Salamanca, Spain
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.